6 independently detected trends connected to this subject, with the latest coverage first.
This hub groups 6 separate news trends connected to Biopharma, spanning July 7, 2026 through September 1, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 45 article observations and 42 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
Novartis and Bristol Myers have paused CAR-T trials after patient deaths, raising safety concerns in the biopharma industry.
Eli Lilly's $2.88 billion acquisition of Merida Biosciences is poised to reshape the autoimmune disease treatment landscape.
Massachusetts' biotech sector faces a paradox: job losses amid a rebound in investment.
Replimune's melanoma drug wins FDA approval on third attempt, but stock price falls.
Anthropic is aggressively expanding into the biopharma sector through a 100-day sprint involving Nobel hires, M&A activity, and new research tools.
Vertex Pharmaceuticals is entering the endocrine disease market with a $10 billion acquisition of Crinetics.